Hyperpigmentation of the hard palate mucosa in a patient with chronic myeloid leukaemia taking imatinib

Hassona Y, Sawair F, Al-Karadsheh O, Scully C (2016) Prevalence and clinical features of pigmented oral lesions. Int J Dermatol 55:1005–1013 Axell T (1976) A prevalence study of oral mucosal lesions in an adult Swedish population. Odontol Rev 36:1–103 Li CC, Malik SM, Blaeser BF, Dehni WJ et al (2012) Mucosal pigmentation caused by imatinib: report of three cases. Head Neck Pathol 6:290–295 Dereure O (2001) Drug-induced skin pigmentation. Epidemiology, diagnosis and treatment. Am J Clin Dermatol 2:253–262 Ciҫek Y, Ertaş U (2003) The normal and pathological pigmentation of oral mucous membrane: a review. J Contemp Dent Pract 4:76–86 Meleti M, Vescovi P, Mooi WJ et al (2008) Pigmented lesions of the oral mucosa and perioral tissues: a flow-chart for the diagnosis and some recommendations for the management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 105:606–616 National Institute for Health and Care Excellence (2012) Guidance on the use of imatinib for chronic myeloid leukaemia, TA70. NICE, London Scheinfeld N (2006) Imatinib mesylate and dermatology part 2: a review of the cutaneous side effects of imatinib mesylate. J Drugs Dermatol 5:228–231 Arora B, Kumar L, Sharma A, Wadhwa J, Kochupillai V (2004) Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate. Ann Oncol 15:358–359 Robert C, Soria JC, Spatz A, le Cesne A, Malka D, Pautier P et al (2005) Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 6:491–500 Tsao AS, Kantarjian H, Cortes J, O'Brien S, Talpaz M (2003) Imatinib mesylate causes hypopigmentation in the skin. Cancer 98:2483–2487 Ena P, Chiarolini F, Siddi GM, Cossu A (2004) Oral lichenoid eruption secondary to imatinib (Glivec). J Dermatolog Treat 15:253–255 Lim DS, Muir J (2002) Oral lichenoid reaction to imatinib (STI 571, Gleevec). Dermatology 205:169–171 Pascual JC, Matarredona J, Miralles J, Conesa V, Borras-Blasco J (2006) Oral and cutaneous lichenoid reaction secondary to imatinib: report of two cases. Int J Dermatol 45:1471–1473 Singh N, Bakhshi S (2007) Imatinib-induced dental hyperpigmentation in childhood chronic myeloid leukemia. J Pediatr Hematol Oncol 29:208–209 Singh O, Agrawal P, Agarwal A, Yadav S (2016) Imatinib induced dental hyperpigmentation chronic myeloid leukemia in adult female. J Assoc Physicians India 64:138 Agrawal P, Singh O, Nigam AK, Upadhyay S (2015) Imatinib induced dental hyperpigmentation in chronic myeloid leukemia in an adult female. Indian J Pharmacol 47:685–686 Lewis DM (2009) Diffuse pigmentation of the palate. J Okla Dent Assoc 100:24–25 Wong M, Sade S, Gilbert M, Klieb HB (2011) Oral melanosis after tyrosine kinase inhibition with imatinib for chronic myelogenous leukemia: report of a case and review of the literature. Dermatol Online J 17:4 Mattsson U, Halbritter S, Mörner Serikoff E et al (2011) Oral pigmentation in the hard palate associated with imatinib mesylate therapy: a report of three cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 111:e12–e16 Resende RG, Teixeira RG, Vasconcelos Fde O et al (2012) Imatinib associated hyperpigmentation of the palate in post-HSCT patient. J Cranio-Maxillo-Facial Surgery 40:e140–e143 Roeker LE, Wolanskyj AP (2014) Imatinib-associated melanosis of the palate. Am J Hematol 89:564 Song HS, Kang HY (2014) Imatinib mesylate-induced hyperpigmentation of the nose and palate. Ann Dermatol 26:532–533 Lyne A, Creedon A, Bailey BM (2015) Mucosal pigmentation of the hard palate in a patient taking imatinib. BMJ Case Rep 16:2015 Meleti M, Mooi WJ, Casparie MK et al (2007) Melanocytic nevi of the oral mucosa—no evidence of increased risk for oral malignant melanoma: an analysis of 119 cases. Oral Oncol 43:976–981 Reddy GJ, Kanth MR, Kumar DR et al (2015) Oral malignant melanoma. J Clin Diagn Res 9:ZL03 De Schepper S, Boucneau J, Lambert J, Messiaen L, Naeyaert JM (2005) Pigment cell-related manifestations in neurofibromatosis type 1: an overview. Pigment Cell Res 18:13–24 Kim IS, Kim ER, Nam HJ, Chin MO, Moon YH, MR O et al (1999) Activating mutation of GS alpha in McCune-Albright syndrome causes skin pigmentation by tyrosinase gene activation on affected melanocytes. Horm Res 52:235–240 Cinotti E, Couzan C, Perrot JL, Habougit C, Labeille B et al (2015) In vivo confocal microscopic substrate of grey colour in melanosis. J Eur Acad Dermatol Venereol 29:2458–2462 Alawi F (2013) Pigmented lesions of the oral cavity: an update. Dent Clin N Am 57:699–710 Hedin CA, Pindborg JJ, Axell T (1993) Disappearance of smoker’s melanosis after reducing smoking. J Oral Pathol Med 22:228–230 Kauzman A, Pavone M, Blanas N et al (2004) Pigmented lesions of the oral cavity: review, differential diagnosis, and case presentations. J Can Dent Assoc 70:682–683 Callender VD, St Surin-Lord S, Davis EC, Maclin M (2011) Postinflammatory hyperpigmentation: etiologic and therapeutic considerations. Am J Clin Dermatol 12:87–99 Vera-Sirera B, Risueńo-Mata P, Ricart-Vaya JM et al (2012) Clinicopathological and immunohistochemical study of oral amalgam pigmentation. Acta Otorrinolaringol Esp 63:376–381 Barrett AW, Scully C (1994) Human oral mucosal melanocytes: a review. J Oral Pathol Med 23:97–103 Gagari E, Rand MK, Tayari L, Vastardis H, Sharma P et al (2006) Expression of stem cell factor and its receptor, C-kit, in human oral mesenchymal cells. Eur J Oral Sci 114:409–415 Kumar B, Saraswat A, Kaur I (2002) Mucocutaneous adverse effects of hydroxyurea: a prospective study of 30 psoriasis patients. Clin Exp Dermatol 27:8–13 McPherson T, Sherman V, Turner R (2009) Imatinib-associated hyperpigmentation, a side effect that should be recognized. J Eur Acad Dermatol Venereol 23:82–83 Romeo U, Palaia G, Fantozzi PJ, Tenore G, Bosco D (2015) A rare case of melanosis of the hard palate mucosa in a patient with chronic myeloid leukemia. Case Rep Dent 2015;9:817094